Home » Archive

Xconomy

News, Syndication, Xconomy »

Xconomist of the Week: Roger Perlmutter’s Parting Thoughts on Amgen

Posted by sandiegobiotech March 1st, 2012 .
No Comments

[Updated: 1:50 pm PT] Roger Perlmutter had a long run by biotech standards, a full 11 years, to put his stamp on R&D at Amgen. Some of the work he oversaw was unequivocally good (denosumab for…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

Concert Nabs $200M Deal From Avanir to Make Psych Drugs

Posted by sandiegobiotech February 29th, 2012 .
No Comments

Lexington, MA-based Concert Pharmaceuticals has found a second partner looking to take advantage of its technology for making deuterium-modified drugs. Concert is announcing today that Aliso Viejo,…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

Bruce Booth, a LifeSciVC Shining Some Much-Needed Light on Biotech

Posted by sandiegobiotech February 27th, 2012 .
No Comments

Techies who want to learn about high-tech venture capital learn quickly they must read blogs by guys like Fred Wilson and Brad Feld. They are insiders who speak with clear, consistent, and insightful…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

San Diego Life Sciences Roundup: Receptos, Vital Therapies, & More

Posted by sandiegobiotech February 23rd, 2012 .
No Comments

Funding deals accounted for much of the life sciences news over the past week. We’ve got it all wrapped up here. —San Diego-based Receptos, which is using the structure of cellular G protein-coupled…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

San Diego Life Sciences Roundup: Receptos, Vital Therapies, & More

Posted by sandiegobiotech February 23rd, 2012 .
No Comments

Funding deals accounted for much of the life sciences news over the past week. We’ve got it all wrapped up here. —San Diego-based Receptos, which is using the structure of cellular G protein-coupled…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

San Diego Life Sciences Roundup: Receptos, Vital Therapies, & More

Posted by sandiegobiotech February 23rd, 2012 .
No Comments

Funding deals accounted for much of the life sciences news over the past week. We’ve got it all wrapped up here. —San Diego-based Receptos, which is using the structure of cellular G protein-coupled…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

Vertex Stays in HepC Game, as All-Oral Combo Passes Small Study

Posted by sandiegobiotech February 23rd, 2012 .
No Comments

Vertex Pharmaceuticals, some investors theorized in recent months, was about to be left in the dust by other companies with more effective drugs in development against hepatitis C. Today, Vertex…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

Reinventing Biotech: Meet Corey Goodman, Kevin Starr & More April 3

Posted by sandiegobiotech February 23rd, 2012 .
No Comments

When people think of innovation in biotech, it’s usually about the whiz-bang science behind new drugs. But after years of sticking to a pretty standard playbook, we’re now starting to see more…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

Oh, And One More Thing: A Wowser Moment in DNA Sequencing

Posted by sandiegobiotech February 21st, 2012 .
No Comments

[Updated and corrected, 10:15 am PT] Steve Jobs used to love being on stage, getting the audience in the palm of his hand. Famously, he’d say, “Oh, and one more thing,” to build suspense right before…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

SD Life Sciences Roundup: Celladon, Gen-Probe, Organovo, and More

Posted by sandiegobiotech February 16th, 2012 .
No Comments

Here’s our wrap-up of news from San Diego’s life sciences sector since last week. —San Diego’s Celladon raised $43 million to recapitalize the company and to conduct a 200-patient study of a gene…

[[Click headline to continue reading.]]

More...